Every 10-Q that Rani Therapeutics Holdings, Inc. (RANI) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow RANI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full RANI filings page.
Rani Therapeutics Holdings, Inc. reported for the period ended June 30, 2026 that it remains a clinical-stage company developing its RaniPill oral biologics platform, with two configurations, RaniPill GO and high‑capacity RaniPill HC. Contract revenue reached $1.7 million in the quarter and $3.4 million year‑to‑date, primarily from a Chugai collaboration, compared with minimal revenue a year earlier. Operating expenses were $10.5 million for the quarter and $20.6 million for the first six months.
Net loss was $8.4 million for the quarter and $16.4 million year‑to‑date. Cash, cash equivalents and marketable securities totaled $53.4 million, and the company states this should fund operations for at least twelve months from issuance of these financial statements. In May 2026 it raised $20.0 million gross through a Class A share and pre‑funded warrant financing. Rani continues its RT‑114 obesity program with ProGen and reported Phase 1a data showing RT‑114 oral delivery achieved bioavailability exceeding 150% versus a matched subcutaneous dose.
Rani Therapeutics Holdings, Inc. reported higher contract revenue and a smaller overall loss for the three months ended March 31, 2026, while remaining a clinical‑stage company with no product sales yet. Contract revenue rose to $1.7 million, primarily from its Chugai collaboration, compared with $0.2 million a year earlier.
Total operating expenses fell to $10.0 million from $12.2 million, as both research and development and general and administrative costs declined, helped by lower compensation expense. Net loss narrowed to $8.0 million from $12.7 million, with net loss attributable to Rani essentially flat at about $7.0 million, or $(0.04) per Class A share versus $(0.22).
Rani ended March 31, 2026 with $43.4 million in cash, cash equivalents, and marketable securities and total assets of $51.9 million. Management believes this liquidity will fund operations for at least twelve months from issuance of these financial statements as it advances its RaniPill oral biologics platform, including the RT‑114 Phase 1 obesity trial with ProGen and the hemophilia collaboration with Chugai.
Rani Therapeutics (RANI) filed its Q3 2025 10‑Q, reporting lower operating expenses and a narrower quarterly loss. Q3 operating expenses were $7.3 million versus $11.8 million a year ago, driving a net loss of $7.9 million compared to $12.7 million in Q3 2024. Year to date, the company recorded contract revenue of $172,000 and a net loss of $31.9 million.
Liquidity remained tight at quarter‑end with cash, cash equivalents and restricted cash of $4.6 million, total assets of $10.1 million, and current debt of $13.5 million. Stockholders’ equity stood at a deficit of $12.0 million. Management notes that October 2025 financing events, a Chugai license and collaboration upfront, Series D warrant exercises, and a lender debt conversion alleviated substantial doubt about going concern for the next 12 months.
During 2025, Rani raised funds via a July securities purchase agreement ($3.0 million gross) and $3.9 million in cash from warrant exercises tied to a May letter agreement, issuing 13,160,172 Series D warrants at a $0.65 exercise price. As of October 31, 2025, Rani had 97,541,221 Class A shares and 23,970,359 Class B shares outstanding.